Dr. Cohen on the Value of PFS as an Endpoint in Head and Neck Cancer

09 Apr, 2019 ,
OncLiveTV
OncLiveTV
09 Apr, 2019 ,

Ezra Cohen discusses the value of progression-free survival (PFS) as an endpoint in head and neck cancer trials.  PFS may not be the best endpoint to use when comparing these agents with cytotoxic agents or targeted therapies.

Full content

Ezra Cohen discusses the value of progression-free survival (PFS) as an endpoint in head and neck cancer trials.  PFS may not be the best endpoint to use when comparing these agents with cytotoxic agents or targeted therapies.